Teleflex Q2 revenue up 4.7% pro forma; cuts revenue guidance, raises adjusted EPS outlook

TELEFLEX INC

Q2 revenue $570.3M (+28.9% reported, +4.7% pro forma adj. constant currency); GAAP EPS $0.96, adj. EPS $1.76.
Full-year 2026 pro forma adj. constant currency revenue growth guidance reduced to 3.5%-4.5%; GAAP EPS cut to $2.54-$2.84.
Adjusted EPS guidance raised to $6.90-$7.20; includes ~19% adj. operating margin and $250M share repurchase in Q2.
Completed OEM divestiture for $1.5B cash; paid off $700M Term Loan A-2; new $500M 5.875% senior notes due 2032.
FDA approved EZPLAZ freeze-dried plasma; Freesolve BIOMAG-II enrollment completed ahead of schedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.